Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 17/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5030311 | 1.00 | CCR2 (0.41) | CCR2RAB9ACYP2D6KCNH2CCR5 | |
| SCHEMBL5033602 | 0.89 | CCR2 (0.49) | CCR2RAB9ACYP2D6KCNH2CCR5 | |
| SCHEMBL5033600 | 0.89 | CCR2 (0.49) | CCR2RAB9ACYP2D6KCNH2CCR5 | |
| SCHEMBL5033606 | 0.89 | CCR2 (0.49) | CCR2RAB9ACYP2D6KCNH2CCR5 | |
| SCHEMBL5027236 | 0.87 | CCR2 (0.48) | CCR2CYP2D6KCNH2 | |
| SCHEMBL5027245 | 0.87 | CCR2 (0.48) | CCR2CYP2D6KCNH2 | |
| SCHEMBL5030345 | 0.84 | CCR2 (0.53) | CCR2CYP2D6KCNH2CCR5 | |
| SCHEMBL5030336 | 0.84 | CCR2 (0.53) | CCR2CYP2D6KCNH2CCR5 | |
| SCHEMBL5030326 | 0.79 | CCR2 (0.54) | CCR2RAB9ACYP2D6KCNH2CCR5 | |
| SCHEMBL5233939 | 0.76 | CCR2 (0.40) | CCR2RAB9ACYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | CCR2 3/4885RAB9A 2580/4885CYP2D6 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.